Eikon Therapeutics, Inc. EIKN
5.55 USD -0.13 (-2.29%)
At closeNov 3, 2026, 4:00 PM EST
5.55 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
5.35 Day range 6.02
5.01 52-week range 17.40
- YTD
- -63.00%
- 1 year
- -63.00%
- Market cap
- 300.62M
- EPS (ttm)
- -8.32
- YTD return
- -63.00%
- 1-year return
- -63.00%
- Volume
- 556.05K
- Avg volume
- 564.01K
- Open
- 5.68
- Previous close
- 5.68
- Day's range
- 5.35 – 6.02
- 52-week range
- 5.01 – 17.40
YTD -9.47 (-63.13%)
Financials — quick view
EIKN Revenue — quarterly 0
EIKN Net income — quarterly -88.41M
EIKN EPS — quarterly -1.63
News
Eikon Therapeutics to Participate in Multiple Investor Conferences in November 
Eikon Therapeutics Announces EIK1001 Plus Pembrolizumab And Chemotherapy In First-Line, Stage 4 Non-Small Cell Lung Cancer Demonstrates Durable Effect In Combination With Standard-Of-Care, With Tolerability Profile Supportive Of Systemic Administration In An Outpatient Setting 
Eikon Therapeutics Presents Initial And Updated Data For EIK1003 And Initial Data For EIK1004 And EIK1005 At ESMO 2026; Initial And Updated Cohort Data From Ongoing Phase 1/2 Study Of EIK1003 Continue To Support Potentially Differentiated Profile 
HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23 
Eikon Therapeutics Files Submits Investigational New Drug Application To FDA To Evaluate EIK1006 To Treat Advanced Metastatic Prostate Cancer
Your note
Sign in to keep a note on EIKN — it syncs with the Stock Master app.